TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
ENTA

Enanta Pharmaceuticals Inc

Healthcare · Biotechnology

12.20$ -3.4% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ENTA
Line item 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – +99.9% +124.2% +32.9% +58.3% +14.3% +16.1% +26.8% +18.3% +0.2% -10.2% -13.7% +21.5% -18.5% -25.5%
– – +88.5% +121.3% +3.1% +58.0% +36.0% +2.4% +59.9% +5.6% +8.7% -27.0% -2.3% +35.6% -29.1% -31.9%
– – +53.7% -15.7% +246.5% -29.2% -23.7% +296.2% -2.7% -19.8% +70.1% -34.3% -23.1% +94.1% -56.4% -13.3%
– – +87.6% +131.9% -10.6% +60.0% +44.7% +6.5% +38.0% +8.6% +15.3% -36.9% +2.1% +48.4% -32.9% -23.9%
– – +1,027.2% -45.9% +182.3% +249.8% -18.3% -17.3% +533.2% -23.6% -54.2% +158.9% -19.4% -19.2% -2.5% -82.2%
– – – -100.0% – +0.0% -100.0% – – – – – – – – –
– – +14.4% +83.5% +60.8% +226.5% +36.0% +0.6% +4.0% +30.5% -21.3% +23.9% +179.2% – – –
– – – – – – – – – – – – – – – –
– – – – – – – – – – – – – – – –
– – -94.8% -21.0% +3.9% +45.8% +15.1% +120.1% -17.7% +33.0% +28.8% +17.7% +43.0% +314.4% +0.9% -12.8%
– – +166.8% -21.1% +4.9% +41.3% +17.7% +166.0% -23.6% +41.1% +6.8% +49.7% -17.5% +110.5% -8.4% -15.6%
– – – – – -65.8% +5.8% +8.2% – – – -1.4% -31.2% +82.5% +582.2% -5.9%
– – +227.0% -20.0% +26.5% -17.7% +118.9% +10.0% +27.8% +41.0% -14.2% +66.3% -37.1% -31.7% +95.3% -75.7%
– – – – – – -2.5% +379.2% +113.6% +0.0% – – – – – –
– – – +151.5% +34.6% +58.9% +14.3% +11.8% +30.5% +17.5% -1.5% -12.3% -19.6% -32.6% -40.6% -49.8%
– – – – – – +362.3% +64.1% +158.7% +39.5% -22.1% -61.9% -250.6% – – –
– -9.3% -27.0% +4.6% +96.0% +0.6% -0.4% +1.0% +6.4% +1.5% -4.9% +1.2% +2.1% +1.8% +0.9% +0.8%

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?